Betaville Intelligence

UNCOOKED ALERT: Viking Therapeutics Inc said to ... - Part 3

Eli Lilly and Company's pursuit of Viking Therapeutics, the US-listed biopharmaceutical company developing obesity drugs, may have stalled.

People following the situation had heard speculation Eli Lilly had been trying to buy Viking for between $40 and $50 a share with a view to announcing a deal last week.

However, Viking decided the indicative price wasn't good enough and opted to announce its drug data, said people following the situation...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Tuesday, 27 February 2024, 4:21 pm

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation